SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease
Lead SponsorSaegis Pharmaceuticals
StatusCompleted No Results Posted
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
Inclusion Criteria: 55 to 90 years of age Diagnosed with mild to moderate Alzheimer's disease Willing caregiver In general good health Exclusion Criteria: Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information. Prohibited Meds: Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)